1 results match your criteria: "Department of Medical Oncology and Beatson Oncology Centre[Affiliation]"
Background: XR5000 is a tricyclic carboxamide that intercalates DNA and inhibits both topoisomerase I and II. The aim of this study was to evaluate the efficacy and tolerability of XR5000 in patients with recurrent glioblastoma multiforme previously untreated with chemotherapy at relapse.
Patients And Methods: Patients received XR5000 at a dose of 3010 mg/m2 as a 120-h central venous infusion every 3 weeks.